Patents by Inventor Amir Razai

Amir Razai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20240166744
    Abstract: This invention relates generally to monoclonal antibodies that recognize CD47, more specifically to CD47 antibodies that do not cause a significant level of agglutination of cells, red blood cell depletion, anemia, and/or platelet depletion, to methods of generating these antibodies, and to methods of using these monoclonal antibodies as therapeutics.
    Type: Application
    Filed: August 16, 2023
    Publication date: May 23, 2024
    Inventors: Brendan ECKELMAN, John Timmer, Amir Razai, Quinn DEVERAUX, Kyle JONES, Mark Lappe
  • NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20210317205
    Abstract: This invention relates generally to monoclonal antibodies that recognize CD47, more specifically to CD47 antibodies that do not cause a significant level of agglutination of cells, red blood cell depletion, anemia, and/or platelet depletion, to methods of generating these antibodies, and to methods of using these monoclonal antibodies as therapeutics.
    Type: Application
    Filed: February 8, 2021
    Publication date: October 14, 2021
    Inventors: Brendan Eckelman, John Timmer, Amir Razai, Quinn Deveraux, Kyle Jones, Mark Lappe
  • Multivalent and multispecific glucocorticoid-induced TNFR-related protein (GITR)-binding single-domain antibody fusion proteins and encoding nucleic acids
    Patent number: 10844129
    Abstract: This disclosure generally provides molecules that specifically engage glucocorticoid-induced TNFR-related protein (GITR), a member of the TNF receptor superfamily (TNFRSF). More specifically, the disclosure relates to multivalent and/or multispecific molecules that bind at least GITR.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: November 24, 2020
    Assignee: Inhibrx, Inc.
    Inventors: John C. Timmer, Kyle S. Jones, Amir Razai, Abrahim Hussain, Katelyn M. Willis, Quinn Deveraux, Brendan P. Eckelman
  • MULTIVALENT AND MULTISPECIFIC GITR-BINDING FUSION PROTEINS
    Publication number: 20190100594
    Abstract: This disclosure generally provides molecules that specifically engage glucocorticoid-induced TNFR-related protein (GITR), a member of the TNF receptor superfamily (TNFRSF). More specifically, the disclosure relates to multivalent and/or multispecific molecules that bind at least GITR.
    Type: Application
    Filed: August 31, 2018
    Publication date: April 4, 2019
    Applicant: Inhibrx, Inc.
    Inventors: John C. TIMMER, Kyle S. JONES, Amir RAZAI, Abrahim HUSSAIN, Katelyn M. WILLIS, Quinn DEVERAUX, Brendan P. ECKELMAN
  • CD47 antibodies and methods of use thereof
    Patent number: 9663575
    Abstract: This invention relates generally to monoclonal antibodies that recognize CD47, more specifically to CD47 antibodies that do not cause a significant level of agglutination of cells, to methods of generating these antibodies, and to methods of using these monoclonal antibodies as therapeutics.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: May 30, 2017
    Assignee: InhibRx, LP
    Inventors: Brendan Eckelman, John Timmer, Amir Razai, Quinn Deveraux, Kyle Jones, Peter L. Nguy
  • NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20160251435
    Abstract: This invention relates generally to monoclonal antibodies that recognize CD47, more specifically to CD47 antibodies that do not cause a significant level of agglutination of cells, red blood cell depletion, anemia, and/or platelet depletion, to methods of generating these antibodies, and to methods of using these monoclonal antibodies as therapeutics.
    Type: Application
    Filed: August 31, 2015
    Publication date: September 1, 2016
    Inventors: Brendan ECKELMAN, John TIMMER, Amir RAZAI, Quinn DEVERAUX, Kyle JONES, Mark LAPPE
  • CD47 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20150238604
    Abstract: This invention relates generally to monoclonal antibodies that recognize CD47, more specifically to CD47 antibodies that do not cause a significant level of agglutination of cells, to methods of generating these antibodies, and to methods of using these monoclonal antibodies as therapeutics.
    Type: Application
    Filed: April 29, 2015
    Publication date: August 27, 2015
    Inventors: Brendan ECKELMAN, John TIMMER, Amir RAZAI, Quinn DEVERAUX, Kyle JONES, Peter L. NGUY
  • CD47 antibodies and methods of use thereof
    Patent number: 9045541
    Abstract: This invention relates generally to monoclonal antibodies that recognize CD47, more specifically to CD47 antibodies that do not cause a significant level of agglutination of cells, to methods of generating these antibodies, and to methods of using these monoclonal antibodies as therapeutics.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: June 2, 2015
    Assignee: InhibRx LLC
    Inventors: Brendan Eckelman, John Timmer, Amir Razai, Quinn Deveraux, Kyle Jones, Peter L. Nguy
  • Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
    Publication number: 20140140989
    Abstract: This invention relates generally to monoclonal antibodies that recognize CD47, more specifically to CD47 antibodies that do not cause a significant level of agglutination of cells, red blood cell depletion, amenia, and/or platelet depletion, to methods of generating these antibodies, and to methods of using these monoclonal antibodies as therapeutics.
    Type: Application
    Filed: August 6, 2013
    Publication date: May 22, 2014
    Applicant: INHIBRX LLC
    Inventors: Brendan Eckelman, John Timmer, Amir Razai, Quinn Deveraux, Kyle Jones, Mark Lappe